Dr. Hooper is a professor of cancer biology and neurological surgery and the section chief for translational research in the department of neurological surgery’s tumor division at Thomas Jefferson University. He has made important contributions to the understanding of immunity, particularly with respect to therapeutic and pathological mechanisms acting in central nervous system tissues, with over 140 peer-reviewed, full-length publications.
Dr. Hooper’s work has led to novel immune therapies for rabies infection, neuroinflammation, and cancer with 10 issued U.S. patents and 19 international patents that have been licensed to five companies in the U.S. and abroad. He is the founding president of the Jefferson Chapter of the National Academy of Inventors and a fellow of the National Academy of Inventors. He is a co-founder of Imvax Inc., a startup company that has licensed Jefferson systemic cancer immunotherapy technology developed by Dr. Hooper and his colleagues. He serves on the editorial board of a number of journals including the Journal of Immunology and Scientific Reports and has been the recipient of numerous grants from the National Institutes of Health as well as other national and international agencies.Dr. Hooper received his doctorate in immunology from McGill University in Montreal, Quebec, Canada, and did his post-doctoral training at the University of Bristol, England.
